Technology has ushered in an era of unprecedented discovery about the workings of the human brain. With the deluge of brain science, there’s never been a greater need for collaboration and partnership to translate data and theory into marketable solutions for survivors of traumatic brain injury.
MINNEAPOLIS (PRWEB) January 30, 2018
Arrowhead Publishers has opened registration for its 8th Annual Traumatic Brain Injury Conference, to take place May 16-17 at The Westin Arlington Gateway, just outside Washington D.C. This conference will bring together leaders and high-level executives from the pharmaceutical, biotech, academic and government communities to discuss new avenues of research in the field of traumatic brain injury and the latest advances in the field.
“Technology has ushered in an era of unprecedented discovery about the workings of the human brain,” said John Waslif, Managing Director of Arrowhead Publishers. “With new brain science learnings available constantly, there’s never been a greater need for collaboration and partnership to translate data and theory into marketable solutions for survivors of traumatic brain injury.”
This event provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made towards better diagnosis, treatment and long-term care for TBI survivors. At this annual event, physicians, nurses, neurosurgeons, scientists, and drug/diagnostic developers from all over the world network and learn from one another.
The selection process for conference speakers is in progress, to join these featured speakers on the agenda:
Ramon Diaz-Arrastia, MD, Ph.D., Associate Director for Clinical Research, Center for Neurodegeneration & Repair; Director of Traumatic Brain Injury Clinical Research Center; Presidential Professor of Neurology, Penn Medicine, University of Pennsylvania
Dr. Diaz-Arrastia is highly respected for his extensive research to develop novel therapies and better predict patient outcomes after traumatic brain injury, by combining imaging with genomic and tissue biomarkers. His research to understand the molecular-, cellular- and tissue-level mechanisms of brain injury and neuroregeneration has contributed to advance collective understanding and fuel others’ research efforts.
Jamshid Ghajar, MD, Ph.D., FACS, PI, Brain Trauma Evidence-based Consortium (B-TEC); Director, Stanford Concussion & Brain Performance Center; Clinical Professor of Neurosurgery, Stanford University School of Medicine
Dr. Ghajar has been at the forefront of concussion research, working for more than two decades to define concussion and develop techniques and tools for rapid, objective concussion assessment. His work has been focused on reducing the risk of brain damage in athletes by improving early diagnosis of concussion and exploring effective approaches to treatment.
Doug Jeffery, Ph.D., Acting Branch Chief, Immunology and Flow Cytometry Brand, Center for Devices & Radiological Health, Office of In Vitro Diagnostics and Radiological Health, Division of Immunology & Hematology Devices, US Food and Drug Administration
Dr. Jeffery has championed FDA outreach to the proteomics community, to help build a clear and useful regulatory pathway that device developers and manufacturers can follow to submit in vitro diagnostic devices. His team has published mock submissions, hosted public workshops, and developed a pre-submission process to help reduce time to market by offering device developers and manufacturers opportunities to receive FDA recommendations and considerations early in the research process.
Cheryl Wellington, Ph.D., Professor, Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health
A history of traumatic brain injury is increasingly recognized as an environmental risk factor for dementia. Dr. Wellington’s research explores how injury severity, number of injuries and age at injury each affect dementia risk, as well as understanding how the neuropathology and clinical presentation of TBI-related syndromes overlap with those of classical dementias.
Susanna Rosi, Ph.D., Professor & Director of Neurocognitive Research, Brain and Spinal Injury Center, Weill Institute for Neuroscience, University of California San Francisco
Dr. Rosi focuses on understanding how neuroinflammation affects the molecular infrastraucture mediating synaptic plasticity after brain injury to develop treatment strategies to manage neurocognitive disfunctions. Recent research by Dr. Rosi and her team have shown promising reversal of cognitive impairment caused by TBI in mice by preventing infiltration of peripherally derived inflammatory cells acutely after injury.
Ross Zafonte, DO, Earle P. and Ida S. Charlton Professor and Chair of the Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital
Dr. Zafonte’s laboratory work has focused on understanding mechanisms of recovery after Brain and Spinal Cord Injury to develop new biotechnologies to aid in recovery.
Conference sessions and panel discussions will address diverse areas of focus related to brain injury, including current clinical management of TBI; advances and opportunities for TBI biomarkers; recovery, regeneration and neuroplasticity; TBI therapeutic preclinical/clinical candidates; outcomes research; large-scale observational studies of TBI; neuroimaging research and practice; emerging tools for diagnosis/assessment of TBIs; and pre-clinical/clinical development models and design.
There are several ways to participate in the 8th Annual Traumatic Brain Injury Conference:
Learn more at http://www.tbiconference.com.
Request a brochure.
Explore sponsorship and exhibit opportunities.
Submit a speaker proposal.
Stay in the loop!
Join The Traumatic Brain Injury R&D Network on LinkedIn.
Follow @TBIConference on Twitter.
Sign up for the mailing list.
# # #
Arrowhead Publishers brings life sciences industry professionals together to help move research forward through learning, networking and professional growth. Arrowhead focuses on offering thoughtfully curated speakers, new research industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Arrowhead conferences cover clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals.